Skip to main content
Back
CORT logo

Corcept Therapeutics Incorporated

Data quality: 100%
CORT
NASDAQ Healthcare Biotechnology
$33.63
▼ $1.01 (-2.92%)
Mkt Cap: 3.58B
Day Range
$33.61 $35.00
52-Week Range
$28.66 $117.33
Volume
1,310,662
50D / 200D Avg
$37.45 / $64.86
Prev Close
$34.64

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 35.9 0.4
P/B 5.5 2.9
ROE % 15.0 3.8
Net Margin % 13.1 3.9
Rev Growth 5Y % 20.1 10.0
D/E 0.0 0.2

Key Takeaways

Revenue grew 20.10% annually over 5 years — strong growth
Earnings declined -28.68% over the past year
ROE of 15.01% — decent returns on equity
Debt/Equity of 0.01 — conservative balance sheet
Generating 141.79M in free cash flow
P/E of 35.90 — premium valuation

Growth

Revenue Growth (5Y)
20.10%
Revenue (1Y)12.79%
Earnings (1Y)-28.68%
FCF Growth (3Y)5.70%

Quality

Return on Equity
15.01%
ROIC5.14%
Net Margin13.09%
Op. Margin5.88%

Safety

Debt / Equity
0.01
Current Ratio2.92
Interest Coverage0.00

Valuation

P/E Ratio
35.90
P/B Ratio5.52
EV/EBITDA77.30
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 12.79% Revenue Growth (3Y) 25.64%
Earnings Growth (1Y) -28.68% Earnings Growth (3Y) -3.10%
Revenue Growth (5Y) 20.10% Earnings Growth (5Y) -2.99%
Profitability
Revenue (TTM) 761.41M Net Income (TTM) 99.65M
ROE 15.01% ROA 11.91%
Gross Margin 98.30% Operating Margin 5.88%
Net Margin 13.09% Free Cash Flow (TTM) 141.79M
ROIC 5.14% FCF Growth (3Y) 5.70%
Safety
Debt / Equity 0.01 Current Ratio 2.92
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio 35.90 P/B Ratio 5.52
P/S Ratio 4.70 PEG Ratio -1.22
EV/EBITDA 77.30 Dividend Yield 0.00%
Market Cap 3.58B Enterprise Value 3.46B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 761.41M 675.04M 482.38M 401.86M 365.98M
Net Income 99.65M 139.73M 106.14M 101.42M 112.51M
EPS (Diluted) 0.82 1.23 0.94 0.87 0.89
Gross Profit 748.43M 664.16M 475.89M 396.47M 360.70M
Operating Income 44.80M 136.95M 107.28M 112.63M 124.48M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 836.65M 840.55M 621.52M 583.43M 423.76M
Total Liabilities 188.85M 160.96M 114.81M 81.59M 47.95M
Shareholders' Equity 647.81M 679.59M 506.71M 501.84M 375.81M
Total Debt 6.11M 6.94M 151,000.0 1.14M 526,000.0
Cash & Equivalents 120.50M 127.67M 135.55M 66.33M 77.62M
Current Assets 485.46M 471.60M 458.64M 499.25M 266.46M
Current Liabilities 166.09M 140.77M 104.51M 72.49M 47.54M

Strategy Scores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#976 of 1024
18

Recent Activity

Entered Cash Flow Compounder
Mar 24, 2026